Table 1.
Omega-3 Study Baseline Demographic and Medical Characteristics
| Characteristic | Group Assignment
|
P-value | |
|---|---|---|---|
| Placebo (n=60) | Omega3 (n=62) | ||
|
| |||
| Age (years) | 58.6 ± 8.5 | 58.1 ± 9.4 | .79 |
|
| |||
| Gender (Female) | 31.7% | 35.5% | .66 |
|
| |||
| Caucasian | 81.7% | 79.0% | .71 |
|
| |||
| Education > 12 years | 61.7% | 64.5% | .74 |
|
| |||
| BMI (kg/m2) | 32.6 ± 7.3 | 33.8 ± 7.3 | .39 |
|
| |||
| Cigarette Smoker | |||
| Ever | 75.0% | 77.4% | .75 |
| Current | 21.7% | 27.4% | .46 |
|
| |||
| Hypertension | 80.0% | 74.2% | .45 |
|
| |||
| Diabetes | 43.3% | 29.0% | .10 |
|
| |||
| History of MI/ACS | 55.0% | 64.5% | .28 |
|
| |||
| History of CABG | 36.7% | 32.3% | .61 |
|
| |||
| History of PTCA | 66.7% | 62.9% | .66 |
|
| |||
| Canadian Cardiovascular Society Angina class | .12 | ||
| Asymptomatic | 78.0% | 60.7% | |
| I | 0% | 3.3% | |
| II | 5.1% | 4.9% | |
| III | 1.7% | 9.8% | |
| IV | 15.3% | 21.3% | |
|
| |||
| Fish Consumption (average number of servings per week) | .60 ± .65 | .52 ± .73 | .50 |
|
| |||
| Baseline medications | |||
| Aspirin | 88.3% | 72.6% | .03 |
| Ace inhibitors | 46.7% | 51.6% | .58 |
| Beta blockers | 83.3% | 79.0% | .54 |
| Statins | 75.0% | 72.6% | .76 |
| Calcium channel blockers | 23.3% | 32.3% | .27 |
|
| |||
| Lipids | |||
| Omega-3 Index (DHA + EPA; % in RBC) | 4.6 ± 1.4 | 4.6 ± 1.5 | .95 |
| Total cholesterol (mg/dL) | 175.3 ± 39.8 | 161.1 ± 45.1 | .07 |
| HDL cholesterol (mg/dL) | 43.2 ± 13.0 | 43.3 ± 13.8 | .99 |
| Triglycerides, fasting (mg/dL) | 198.3 ± 135.2 | 161.6 ± 93.3 | .09 |
|
| |||
| Depression | |||
| History of depression | 74.1% | 63.3% | .21 |
| Duration of current depressive episode (months) | 14.1 ± 18.8 | 14.2 ± 15.5 | .98 |
| History of depression treatment | 65.0% | 59.7% | .54 |
*
Continuous variables are reported as means ± standard deviations; categorical variables are listed as percentage of subjects with the characteristic. Chi-square tests and analyses of variance were used to determine significance.